ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Paushak Ltd

NSE: PAUSHAKLTD · BSE: 532742 · Chemicals & Petrochemicals · 23 announcements

Share price
₹611.60
Market cap
₹1,508 Cr
Revenue (annual)
₹218.6 Cr
Net profit (annual)
₹39.33 Cr
P/E (TTM)
31.9×Sector 35.5×
Promoter holding
67.28%+0.00% QoQ
FII holding
0.11%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

18:07 IST NSE
Dividend

Paushak Dividend

The Board of Paushak Limited recommended a final dividend of ₹2.50 per equity share for the financial year. The dividend is subject to shareholder approval at the upcoming Annual General Meeting, the date of which will be announced separately.

17:44 IST NSE
Financial Results

Paushak Financial Results

Paushak Limited reported its audited financial results for the year ended March 31, 2026, and recommended a dividend of Rs. 2.50 per share (50%). The company recorded annual total income of ₹230.71 Crore and profit after tax of ₹39.33 Crore, reflecting its performance in the speciality chemicals segment.

Value
₹2.50 Cr
18:42 IST NSE
Other Announcement

Paushak Other Announcement

Paushak Limited submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The company's registrar confirmed that share certificates received for dematerialisation were processed and cancelled within the mandated timelines. This is a routine regulatory filing with no immediate financial or operational impact.

14:14 IST BSE
Other Announcement

Paushak Other Announcement

CRA Family Trust, a promoter group entity of Paushak Limited, submitted a Chartered Accountant certificate for FY 2025-26. The certificate confirms compliance with a 2020 SEBI Exemption Order regarding trust deed amendments. This is a routine regulatory disclosure with no immediate financial impact on the company.